The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma

Tingting Feng; Zhongzhong Chen; Jianjun Gu; Yuxiu Wang; Jun Zhang; Lingfeng Min

doi:10.1016/j.lungcan.2019.08.032

The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma

Lung Cancer. 2019 Nov:137:19-22. doi: 10.1016/j.lungcan.2019.08.032. Epub 2019 Aug 31.

Authors

Tingting Feng¹, Zhongzhong Chen¹, Jianjun Gu², Yuxiu Wang¹, Jun Zhang², Lingfeng Min³

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China.
² Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou 225001, Jiangsu, China.
³ Department of Respiratory and Critical Care Medicine, Northern Jiangsu People's Hospital, The First Clinical College of Dalian Medical University, Yangzhou 225001, Jiangsu, China. Electronic address: minlingfeng@126.com.

PMID: 31521978
DOI: 10.1016/j.lungcan.2019.08.032

Abstract

Objectives: Anaplastic lymphoma kinase (ALK) has been proven to be another driver oncogene that accounts for 3%-7% of non-small-cell lung cancer, and it is more common in young patients and nonsmokers. ALK rearrangements have been previously identified in about 5.1% of lung adenocarcinoma, including EML4-ALK fusion variants, KIF5B-ALK and TFG-ALK. However, a TNIP2-ALK fusion has not been reported in lung adenocarcinoma. Herein, we described a rare case of ALK-rearranged lung adenocarcinoma responding to crizotinib.

Materials and methods: Immunohistochemistry (IHC) assay and comprehensive next-generation sequencing (NGS) were performed on the aspirated biopsied tumor tissue.

Results: The IHC analysis revealed an ALK-positive tumor, while NGS detected a TNIP2-ALK fusion. The patient achieved continuous remission after treatment with crizotinib (250 mg, twice a day).

Conclusion: This case provides valuable information on the response to crizotinib of patients with TNIP2-ALK fusion and better understanding of ALK-TKI applications in the future. NGS is a new method that can offer effective detection of gene fusion and gene mutations.

Keywords: ALKfusion; NGS; NSCLC; TNIP2; crizotinib.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adaptor Proteins, Signal Transducing / genetics*
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Anaplastic Lymphoma Kinase / genetics*
Crizotinib / therapeutic use*
Female
Gene Rearrangement*
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Middle Aged
Mutation
Oncogene Proteins, Fusion / genetics*
Prognosis
Protein Kinase Inhibitors / therapeutic use

Substances

Adaptor Proteins, Signal Transducing
Oncogene Proteins, Fusion
Protein Kinase Inhibitors
TNIP2 protein, human
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase